These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

105 related items for PubMed ID: 17665323

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
    Steinberg M.
    Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
    [Abstract] [Full Text] [Related]

  • 5. Fully reversible pulmonary arterial hypertension associated with dasatinib treatment for chronic myeloid leukaemia.
    Dumitrescu D, Seck C, ten Freyhaus H, Gerhardt F, Erdmann E, Rosenkranz S.
    Eur Respir J; 2011 Jul; 38(1):218-20. PubMed ID: 21719499
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Imatinib mesylate (Glivec, Gleevec) in the treatment of chronic myelogenous leukemia (CML) and gastrointestinal stromal tumors (GIST).
    Hochhaus A.
    Ann Hematol; 2004 Jul; 83 Suppl 1():S65-6. PubMed ID: 15124676
    [No Abstract] [Full Text] [Related]

  • 12. Imatinib for chronic myeloid leukemia: the impact of its effectiveness and long-term side effects.
    Smith BD.
    J Natl Cancer Inst; 2011 Apr 06; 103(7):527-9. PubMed ID: 21422404
    [No Abstract] [Full Text] [Related]

  • 13. Practical management of dasatinib for maximum patient benefit.
    Galinsky I, Buchanan S.
    Clin J Oncol Nurs; 2009 Jun 06; 13(3):329-35. PubMed ID: 19502192
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. A T315I mutation in e19a2 BCR/ABL1 chronic myeloid leukemia responding to dasatinib.
    Cea M, Cirmena G, Garuti A, Rocco I, Palermo C, Cagnetta A, Moran E, Colombo N, Grasso R, Fugazza G, Gobbi M, Nencioni A, Ballestrero A, Patrone F.
    Leuk Res; 2010 Sep 06; 34(9):e240-2. PubMed ID: 20447687
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Major molecular response achieved with dasatinib in a CML patient with F317L BCR-ABL kinase domain mutation.
    Faber E, Mojzikova R, Plachy R, Rozmanova S, Stastny M, Divoka M, Jarosova M, Indrak K, Divoky V.
    Leuk Res; 2010 Apr 06; 34(4):e91-3. PubMed ID: 19811824
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.